Abstract | OBJECT: The authors evaluated dendritic cell (DC)-based immunotherapy for malignant brain tumor to improve its therapeutic efficacy. METHODS: Dendritic cells were isolated from bone marrow and pulsed with phosphate-buffered saline, Semliki Forest virus (SFV)-LacZ, retrovirus vector GCsap- interleukin (IL)-12, and SFV-IL-12, respectively, to treat mice bearing brain tumors of the B16 cell line. The results indicated that therapeutic immunization with DCs pulsed with SFV-IL-12 prolonged the survival of mice with established tumors. Semliki Forest virus induced apoptosis in DCs, which in turn facilitated the uptake of apoptotic cells by other DCs, thus providing a potential mechanism for enhanced immunogenicity. CONCLUSIONS:
Therapy with DCs that have been pulsed with SFV-mediated IL-12 may be an excellent step in the development of new cancer vaccines. Intratumorally injected DCs that have been transiently transduced with IL-12 do not require pulsing of a source of tumor antigens to induce tumor regression.
|
Authors | Ryuya Yamanaka, Susan A Zullo, Jay Ramsey, Naoki Yajima, Naoto Tsuchiya, Ryuichi Tanaka, Michael Blaese, Kleanthis G Xanthopoulos |
Journal | Journal of neurosurgery
(J Neurosurg)
Vol. 97
Issue 3
Pg. 611-8
(Sep 2002)
ISSN: 0022-3085 [Print] United States |
PMID | 12296646
(Publication Type: Journal Article)
|
Chemical References |
- Interleukin-12
- Interferon-gamma
|
Topics |
- Animals
- Apoptosis
(immunology)
- Bone Marrow Cells
- Brain Neoplasms
(immunology, therapy)
- CD4-Positive T-Lymphocytes
(immunology, metabolism)
- CD8-Positive T-Lymphocytes
(immunology)
- Dendritic Cells
(immunology, virology)
- Genetic Therapy
- Genetic Vectors
- Glioma
(immunology, therapy)
- Immunotherapy, Active
- Interferon-gamma
(biosynthesis)
- Interleukin-12
(genetics, immunology)
- Mice
- Mice, Inbred C57BL
- Semliki forest virus
(genetics)
- Transduction, Genetic
- Tumor Cells, Cultured
(transplantation)
|